Led · Equity · Nov 2021

Manteia researches deep learning, data technologies, and traditional algorithms to build tools for radiotherapy. Its core products include an adaptive radiation therapy (ART) system and related product modules, a library of common radiotherapy algorithm components and plugins, and deep-learning-based real-time analysis and training systems. These products are designed to improve radiotherapy precision and clinical efficiency. Manteia recently completed a B round raising ¥110 million. The financing was led by Zhongke Haichuang, associated with the Ministry of Science and Technology's Achievement Transformation Guidance Fund, with participation from Yangming Capital and industry cooperation institutions. The article does not disclose prior rounds, valuation, operating metrics, or the specific instruments used in the deal. Manteia develops adaptive radiotherapy (ART) systems, common product modules, algorithm component libraries, and plug-ins that simulate clinical logic to solve clinical problems. Its product suite includes intelligent planning tools such as automatic contouring, automatic planning, and biological optimization. The team's adaptive radiotherapy research group was established in 2011; the company operates independent and joint laboratories, about 30 global joint R&D units, over 80 research projects, and more than 20 international joint projects. Within one year Manteia obtained product registration in four mainstream markets—FDA, NMPA, CE, and KFDA—and has achieved ISO13485 and MDSAP quality-system certifications. The company has entered more than 300 leading hospitals worldwide, including in the United States, Canada, and South Korea, serving thousands of patients every day. Manteia completed a financing round of RMB 100 million jointly invested by Danlu Capital and Deyi Capital.

Participated · Series C · Feb 2021

Liangyihui is an oncology‑focused digital healthcare platform founded in 2015 that provides content, technology and data‑driven services for doctors, patients, hospitals and pharma. The platform matches needs and supply across oncology treatment pathways and supports hospital patient education and management. It reports the largest online oncology user base, with about 200,000 active oncology doctors and roughly 300,000 oncology patients on the platform. During the COVID‑19 pandemic Liangyihui hosted thousands of free consultations and says tens of thousands of patients benefited from its online doctor‑patient links. Liangyihui also operates an internet hospital and plans to further evolve into a technology‑ and data‑driven digital oncology services platform serving pharmaceutical companies, clinicians, hospitals and patients. The company offers digital marketing and market‑access services for drugmakers alongside clinician education and IP building for oncologists.

Led · Series A · Dec 2018

Juventas (合源生物) focuses on developing CAR-T and cell therapy medicines. The company is building a CAR-T drug R&D platform to support its therapeutic pipeline. Funds from the recent financing will support construction of that platform and the implementation of the CNCT19 clinical trial. Management says the capital will accelerate translation of CAR-T and other cell therapy research into clinical development. The announcement identifies the company by its Chinese name and English trade name Juventas. No operating metrics or prior financial details were disclosed in the article.